Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 9061

PREEMPT Act

Rep. Kean Leads Bipartisan Bill to Improve Preeclampsia Testing for Medicaid Patients

The PREEMPT Act was recently introduced and is currently being reviewed by the House Committee on Energy and Commerce. It is in the early stages of the legislative process and is not yet scheduled for a vote. The bill is actively moving through the committee phase.

Legislative Progress

House
Senate
President
Law
Could go either way

The bill has support from both parties and addresses a major health crisis, but it still needs to move through the committee process.

Key Points

Healthcare

Impact Analysis

Personal Impact

Life & Work

Pregnant women on Medicaid or CHIP would benefit from clearer guidelines on preeclampsia screening, which could lead to earlier detection and treatment. Preeclampsia contributes to up to 15% of maternal deaths and 15 to 20% of preterm births, so better screening could meaningfully improve outcomes. However, the bill only requires guidance, not mandatory coverage, so real-world impact depends on state action.

Preeclampsia and related cardiovascular and hypertensive disorders of pregnancy are one of the leading causes of maternal mortality and morbidity in the United States, contributing to up to 15 percent of all maternal deaths
2
2
2
4
+2
ImpactCertaintyScopeDurationSentiment

Programs

Milestones

2 milestones2 actions
May 29, 2026House

Referred to the House Committee on Energy and Commerce.

May 29, 2026

Introduced in House

The bill was officially filed and given a number. It now enters the legislative queue.

Votes

No votes have been recorded for this legislation yet.

Source Information

Document Type

Congressional Bill

Official Title

PREEMPT Act

Bill NumberHR 9061
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the House Committee on Energy and Commerce.

Sponsor

Cosponsors

(3)
D: 2R: 1

Analysis generated by AI. Always verify with official sources.